Psyence Biomedical (PBM) Common Equity (2023 - 2026)

Psyence Biomedical's Common Equity history runs 4 years deep, the most recent figure standing at $16.9 million for Q1 2026.

• On a quarterly basis, Common Equity rose 152.07% year-over-year to $16.9 million in Q1 2026; TTM through Mar 2026 was $16.9 million, a 152.07% increase from a year earlier, with the FY2026 full-year figure at $16.9 million, up 152.07% from the prior year.
• Common Equity improved to $16.9 million in Q1 2026 per PBM's latest filing, from $11.9 million in the prior quarter.
• Across five years, Common Equity topped out at $52.9 million in Q3 2024 and bottomed at -$16068.7 billion in Q3 2023.
• The 4-year median for Common Equity is $9.3 million (2025), against an average of -$2678.1 billion.
• Biggest YoY gain for Common Equity was 161.26% in 2025; the steepest drop was 77.58% in 2025.
• Year by year, Common Equity stood at -$16068.7 billion in 2023, then jumped by 100.0% to $52.9 million in 2024, then tumbled by 77.58% to $11.9 million in 2025, then soared by 42.78% to $16.9 million in 2026.
• Per Business Quant, the three latest PBM Common Equity figures stand at $16.9 million (Q1 2026), $11.9 million (Q3 2025), and $6.7 million (Q1 2025).